Quantitative analysis of PD-1+ TILs
| Clinical feature . | No. of patients . | Median TILs per mm2 (range) . | P* . |
|---|---|---|---|
| Age, years | |||
| >60 | 181 | 21 (0-1288) | NS |
| ≤60 | 55 | 21 (0-1041) | |
| ECOG PS | |||
| >1 | 74 | 30 (0-241) | NS |
| 0 or 1 | 162 | 19 (0-1288) | |
| B symptoms | |||
| Present | 57 | 12 (0-802) | .024 |
| Absent | 179 | 29 (0-441) | |
| Serum LDH | |||
| Elevated | 151 | 18 (0-1082) | NS |
| Normal | 85 | 37 (0-589) | |
| Serum sIL-2R | |||
| Elevated | 188 | 20 (0-326) | NS |
| Normal | 41 | 37 (0-1196) | |
| Extranodal sites | |||
| Present | 98 | 15 (0-1196) | .042 |
| Absent | 98 | 39 (0-1288) | |
| Bulky mass | |||
| Present | 36 | 10 (0-692) | .041 |
| Absent | 196 | 27 (0-1288) | |
| Ann Arbor stage | |||
| III or IV | 137 | 21 (0-1288) | NS |
| I or II | 99 | 21 (0-1196) | |
| DLBCL subtype | |||
| GCB | 97 | 40 (0-1196) | .034 |
| Non-GCB | 139 | 18 (0-1288) | |
| EBV-ISH | |||
| Positive | 24 | 58 (0-802) | NS |
| Negative | 212 | 19 (0-802) | |
| mPD-L1 | |||
| Positive | 47 | 10 (0-1196) | .017 |
| Negative | 161 | 29 (0-1288) | |
| PD-L1 | |||
| Positive | 28 | 3 (0-476) | <.0001 |
| Negative | 208 | 31 (0-1288) |
| Clinical feature . | No. of patients . | Median TILs per mm2 (range) . | P* . |
|---|---|---|---|
| Age, years | |||
| >60 | 181 | 21 (0-1288) | NS |
| ≤60 | 55 | 21 (0-1041) | |
| ECOG PS | |||
| >1 | 74 | 30 (0-241) | NS |
| 0 or 1 | 162 | 19 (0-1288) | |
| B symptoms | |||
| Present | 57 | 12 (0-802) | .024 |
| Absent | 179 | 29 (0-441) | |
| Serum LDH | |||
| Elevated | 151 | 18 (0-1082) | NS |
| Normal | 85 | 37 (0-589) | |
| Serum sIL-2R | |||
| Elevated | 188 | 20 (0-326) | NS |
| Normal | 41 | 37 (0-1196) | |
| Extranodal sites | |||
| Present | 98 | 15 (0-1196) | .042 |
| Absent | 98 | 39 (0-1288) | |
| Bulky mass | |||
| Present | 36 | 10 (0-692) | .041 |
| Absent | 196 | 27 (0-1288) | |
| Ann Arbor stage | |||
| III or IV | 137 | 21 (0-1288) | NS |
| I or II | 99 | 21 (0-1196) | |
| DLBCL subtype | |||
| GCB | 97 | 40 (0-1196) | .034 |
| Non-GCB | 139 | 18 (0-1288) | |
| EBV-ISH | |||
| Positive | 24 | 58 (0-802) | NS |
| Negative | 212 | 19 (0-802) | |
| mPD-L1 | |||
| Positive | 47 | 10 (0-1196) | .017 |
| Negative | 161 | 29 (0-1288) | |
| PD-L1 | |||
| Positive | 28 | 3 (0-476) | <.0001 |
| Negative | 208 | 31 (0-1288) |
ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; sIL-2R, soluble interleukin-2 receptor; NS, not significant.
Wilcoxon signed-rank test